Digital Therapeutics refers to evidence-based therapeutic interventions delivered through software and designed to prevent, manage or treat a medical disorder or condition. Unlike general health and wellness applications, Digital Therapeutics are intended to have a therapeutic function and are typically developed around defined clinical objectives, intervention mechanisms and evidence requirements. They may deliver behavioural interventions, structured exercises, cognitive techniques, education, reminders or other software-mediated therapeutic content.
Depending on the particular product and jurisdiction, Digital Therapeutics may be used independently, alongside conventional treatment or under the supervision of a healthcare professional. The central concept is therefore therapeutic software rather than merely digital information. The term is sometimes abbreviated as DTx and is distinct from broader categories of digital health because digital health includes many technologies that are not intended to provide a therapeutic intervention.
The emergence of Digital Therapeutics reflects the convergence of software engineering, behavioural science, clinical medicine and evidence-based healthcare. Earlier healthcare software frequently focused on records, administration, communication or education, while later applications increasingly attempted to deliver structured interventions directly to patients. Smartphones and ubiquitous computing made it practical to provide therapeutic content repeatedly outside clinical settings. The development of remote monitoring and connected devices also allowed some interventions to respond to measurements or user behaviour.
As the field matured, greater emphasis was placed on clinical trials, outcome measurement, product quality and regulatory classification. This distinguishes Digital Therapeutics from the earlier generation of loosely defined wellness software in which claims about health benefits were often not supported by the same level of clinical evidence expected for established therapeutic interventions.
A Digital Therapeutics intervention can be designed around a particular clinical mechanism. For behavioural conditions, software may deliver structured cognitive or behavioural exercises, while other interventions can support adherence, rehabilitation or management of chronic conditions. Some systems use personalised pathways that alter content according to user responses or measurements, while others provide a fixed programme. The software may collect information about engagement, symptoms, performance or physiological variables and use that information to determine subsequent content.
However, personalisation must be distinguished from genuine clinical adaptation: changing an interface or recommendation based on user behaviour does not necessarily mean that the intervention has been clinically validated for every subgroup. The therapeutic mechanism, intended population, dosing or frequency of use and measurable outcome should all be defined sufficiently clearly to support evaluation.
Clinical evidence is a defining consideration for Digital Therapeutics. Developers can evaluate products through feasibility studies, controlled trials, comparative studies and other forms of clinical research depending on the intervention and intended claims. Outcomes might include symptom severity, functional performance, adherence, quality of life or clinically relevant physiological measures. Engagement metrics such as number of sessions or time spent using an application are useful for understanding use but are not themselves proof of therapeutic effectiveness.
A product can be highly engaging without producing meaningful clinical benefit, while a clinically effective intervention may be used relatively infrequently. Evidence must therefore connect use of the software to appropriate clinical outcomes and should account for the population, comparator, intervention duration and follow-up period.
Digital Therapeutics can involve software architecture similar to other healthcare applications but require additional controls because software behaviour forms part of the intervention itself. Secure authentication, encrypted communication, controlled updates, auditability and appropriate data management can be important. A change to therapeutic content may potentially alter clinical behaviour, meaning that version management and validation can be more consequential than in ordinary consumer applications.
If a product incorporates artificial intelligence, connected sensors or external healthcare systems, the associated risks and validation requirements can become more complex. Accessibility and usability are also clinically relevant because a therapeutic intervention cannot be effective for intended users if its interface, language, navigation or accessibility requirements create barriers to sustained use.
Digital Therapeutics differ from telemedicine because telemedicine primarily concerns remote delivery of healthcare interactions, whereas Digital Therapeutics involve software delivering a therapeutic intervention. They differ from general health applications because therapeutic claims imply a more specific clinical purpose and evidence expectation. They also differ from Electronic Health Records, which primarily manage health information rather than deliver therapy. A Digital Therapeutics product can nevertheless integrate with these technologies.
For example, a clinician may prescribe or recommend software, relevant information may be documented in an Electronic Health Record and the intervention may communicate with a remote monitoring system. These relationships demonstrate that Digital Therapeutics are best understood as a clinical intervention embedded within a larger digital healthcare ecosystem.
Advantages of Digital Therapeutics can include continuous availability, standardised delivery of a defined intervention, scalability and the ability to provide support between conventional clinical encounters. Software can also collect detailed information about engagement and progress that may help evaluate treatment delivery. Limitations include unequal access to suitable devices or connectivity, variable adherence, privacy risks, usability problems and the possibility that an intervention may not generalise across populations.
Digital interventions can also shift some responsibilities from clinicians to patients, which may be inappropriate for people requiring substantial support. Another limitation is that software can change rapidly, creating challenges for long-term evidence and version control. These factors mean that a Digital Therapeutics product should be assessed as a healthcare intervention rather than simply as a convenient mobile application.
Digital Therapeutics occupy an important position within modern digital medicine because they demonstrate that software can function as part of treatment rather than merely as an administrative tool. Their future development is closely related to remote monitoring, personalised interventions, artificial intelligence, connected devices and integrated healthcare systems. At the same time, the defining requirement remains a clinically meaningful therapeutic purpose supported by appropriate evidence.
The term should not automatically be applied to every application that claims to improve health, because broad wellness, education, tracking and lifestyle products do not necessarily constitute therapeutic interventions. Understanding that distinction is essential for interpreting clinical claims, evidence, regulation and the appropriate role of software in patient care.
